An early clinical trial has shown AstraZeneca's (LSE: AZN) vistusertib, when combined with chemotherapy, as capable of causing shrinkage in ovarian and lung cancer in patients for whom other treatments have already failed.
The results, which represent a significant improvement over the current standard of care, show tumor shrinkage in half of patients suffering from ovarian cancer and more than a third of those suffering from lung cancer.
Results from the study, which was funded by AstraZeneca and carried out the Institute for Cancer Research (ICR) in London, were published on Wednesday in Annals of Oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze